Search research articles
Contact Us
Filters
Showing results (281-290 of 351) with videos related to
Page
of 36
Sort By:
JAMA Dermatology
|
June 15, 2017
Clinical, Biochemical, and Genetic Characterization of North American Patients With Erythropoietic Protoporphyria and X-linked Protoporphyria
Manisha Balwani, Hetanshi Naik, Karl E Anderson, et al.
Molecular Medicine (Cambridge, Mass.)
|
February 1, 2013
Loss-of-function ferrochelatase and gain-of-function erythroid-specific 5-aminolevulinate synthase mutations causing erythropoietic protoporphyria and x-linked protoporphyria in North American patients reveal novel mutations and a high prevalence of X-linked protoporphyria
Manisha Balwani, Dana Doheny, David F Bishop, et al.
Virology Journal
|
April 26, 2005
Comparison of amplification enzymes for Hepatitis C Virus quasispecies analysis
Stephen J Polyak, Daniel G Sullivan, Michael A Austin, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
February 2, 2008
Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C
Karen L Lindsay, Chihiro Morishima, Elizabeth C Wright, et al.
Journal of Hepatology
|
September 24, 2022
Clinical features, outcomes, and HLA risk factors associated with nitrofurantoin-induced liver injury
Naga Chalasani, Yi-Ju Li, Andrew Dellinger, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
April 6, 2010
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial
Leonard B Seeff, Gregory T Everson, Timothy R Morgan, et al.
Gastroenterology
|
October 27, 2009
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma
Anna S Lok, Richard K Sterling, James E Everhart, et al.
Hepatology (Baltimore, Md.)
|
June 28, 2000
Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial
A M Di Bisceglie, H L Bonkovsky, S Chopra, et al.
Hepatology (Baltimore, Md.)
|
July 22, 2014
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network
Victor J Navarro, Huiman Barnhart, Herbert L Bonkovsky, et al.
The Journal of Infectious Diseases
|
March 7, 2006
Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C
Chihiro Morishima, Stephen J Polyak, Ranjit Ray, et al.
Page
of 36
Search research articles
Search
Showing results (281-290 of 351) with videos related to
Sort By:
Page
of 36
JAMA Dermatology
|
June 15, 2017
Clinical, Biochemical, and Genetic Characterization of North American Patients With Erythropoietic Protoporphyria and X-linked Protoporphyria
Manisha Balwani, Hetanshi Naik, Karl E Anderson, et al.
Molecular Medicine (Cambridge, Mass.)
|
February 1, 2013
Loss-of-function ferrochelatase and gain-of-function erythroid-specific 5-aminolevulinate synthase mutations causing erythropoietic protoporphyria and x-linked protoporphyria in North American patients reveal novel mutations and a high prevalence of X-linked protoporphyria
Manisha Balwani, Dana Doheny, David F Bishop, et al.
Virology Journal
|
April 26, 2005
Comparison of amplification enzymes for Hepatitis C Virus quasispecies analysis
Stephen J Polyak, Daniel G Sullivan, Michael A Austin, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
February 2, 2008
Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C
Karen L Lindsay, Chihiro Morishima, Elizabeth C Wright, et al.
Journal of Hepatology
|
September 24, 2022
Clinical features, outcomes, and HLA risk factors associated with nitrofurantoin-induced liver injury
Naga Chalasani, Yi-Ju Li, Andrew Dellinger, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
April 6, 2010
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial
Leonard B Seeff, Gregory T Everson, Timothy R Morgan, et al.
Gastroenterology
|
October 27, 2009
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma
Anna S Lok, Richard K Sterling, James E Everhart, et al.
Hepatology (Baltimore, Md.)
|
June 28, 2000
Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial
A M Di Bisceglie, H L Bonkovsky, S Chopra, et al.
Hepatology (Baltimore, Md.)
|
July 22, 2014
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network
Victor J Navarro, Huiman Barnhart, Herbert L Bonkovsky, et al.
The Journal of Infectious Diseases
|
March 7, 2006
Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C
Chihiro Morishima, Stephen J Polyak, Ranjit Ray, et al.
Page
of 36